SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 17, 2003; DOI 10.1182/blood-2003-01-0198. This Article Full Text (PDF) All Versions of this Article: 2003-01-0198v1 102/13/4416    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Siegel, S. Articles by Zeis, M. Search for Related Content PubMed PubMed Citation Articles by Siegel, S. Articles by Zeis, M. Social Bookmarking                   What's this? Submitted January 24, 2003 Accepted June 17, 2003 Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematological malignancies Sandra Siegel, Andreas Wagner, Dieter Kabelitz, Matthias Marget, Joseph Coggin, Adel Barsoum, James Rohrer, Norbert Schmitz, and Matthias Zeis* Department of Hematology, General Hospital St. Georg, Hamburg, Germany Institute of Immunology, University of Kiel, Kiel, Germany Department of Microbiology and Immunology, University of South Alabama College of Medicine, Mobile, AL, USA * Corresponding author; email: mzeis47{at}hotmail.com. The oncofetal-antigen-immature laminin-receptor protein (OFA-iLRP) is a highly conserved protein which is preferentially expressed in fetal tissues and in many types of cancer including hematopoietic malignancies whereas OFA-iLRP is not detectable on normal differentiated adult cells. To investigate whether OFA-iLRP-specific cytotoxic T lymphocytes (CTL) are capable of killing OFA-iLRP-expressing hematological targets, CTL were generated from healthy HLA-A*0201 positive volunteers by incubating T cells with autologous dendritic cells (DC) transfected with OFA-iLRP-RNA. OFA-iLRP-specific CTL lysed HLA-A2+ OFA-iLRP+ tumor cells including several lymphoma and leukemia cell lines, as well as fresh leukemic targets from patients with acute myeloid leukemia (AML) and chronic lymphatic leukemia (CLL) indicating that OFA-iLRP-derived peptides are naturally processed and presented by hematological tumors. Normal OFA-iLRP-negative target cells (CD14+ monocytes, activated B cells, DC, bone marrow cells) were not attacked by OFA-iLRP-specific CTL. Furthermore, in an established murine B-cell lymphoma model (A20) treatment with syngeneic DC transfected with OFA-iLRP-coding RNA resulted in powerful anti-tumor effects in a significant portion of mice. For the first time, these data show that OFA-iLRP can be used as a target for T cell-based immunotherapeutic strategies against hematological malignancies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Almanzar, P. B. Olkhanud, M. Bodogai, C. Dell'Agnola, D. Baatar, S. M. Hewitt, C. Ghimenton, M. K. Tummala, A. T. Weeraratna, K. S. Hoek, et al. Sperm-Derived SPANX-B Is a Clinically Relevant Tumor Antigen That Is Expressed in Human Tumors and Readily Recognized by Human CD4+ and CD8+ T Cells Clin. Cancer Res., March 15, 2009; 15(6): 1954 - 1963. [Abstract] [Full Text] [PDF] J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells Clin. Cancer Res., November 15, 2008; 14(22): 7161 - 7166. [Abstract] [Full Text] [PDF] B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF] M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses Blood, February 1, 2008; 111(3): 1357 - 1365. [Abstract] [Full Text] [PDF] A. Biragyn, R. Schiavo, P. Olkhanud, K. Sumitomo, A. King, M. McCain, F. E. Indig, G. Almanzar, and D. Baatar Tumor-Associated Embryonic Antigen-Expressing Vaccines that Target CCR6 Elicit Potent CD8+ T Cell-Mediated Protective and Therapeutic Antitumor Immunity J. Immunol., July 15, 2007; 179(2): 1381 - 1388. [Abstract] [Full Text] [PDF] R. Schiavo, D. Baatar, P. Olkhanud, F. E. Indig, N. Restifo, D. Taub, and A. Biragyn Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses Blood, June 15, 2006; 107(12): 4597 - 4605. [Abstract] [Full Text] [PDF] S. Siegel, A. Wagner, B. Friedrichs, A. Wendeler, L. Wendel, D. Kabelitz, J. Steinmann, A. Barsoum, J. Coggin, J. Rohrer, et al. Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies. J. Immunol., June 1, 2006; 176(11): 6935 - 6944. [Abstract] [Full Text] [PDF] J. W. Rohrer, A. L. Barsoum, and J. H. Coggin Jr. Identification of Oncofetal Antigen/Immature Laminin Receptor Protein Epitopes That Activate BALB/c Mouse OFA/iLRP-Specific Effector and Regulatory T Cell Clones. J. Immunol., March 1, 2006; 176(5): 2844 - 2856. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020